866-997-4948(US-Canada Toll Free)

EpiCast Report: Irritable Bowel Syndrome - Epidemiology Forecast to 2026

Published By :

GlobalData

Published Date : Nov 2017

Category :

Pharmaceutical

No. of Pages : 37 Pages

EpiCast Report: Irritable Bowel Syndrome - Epidemiology Forecast to 2026

Summary

Irritable bowel syndrome (IBS) is a chronic, relapsing gastrointestinal (GI) disorder that is characterized by abdominal discomfort or pain, bloating, and changes in bowel habit. Due to the lack of a demonstrable structural abnormality to explain these symptoms, IBS is classified as a functional GI disorder.

For this analysis, GlobalData epidemiologists defined IBS using the International Classification of Diseases, Tenth Revision (ICD-10) code for IBS (K58.1). Additionally, to construct the epidemiological forecast for the total and diagnosed prevalent cases of IBS in the 7MM, GlobalData epidemiologists followed the Rome III diagnostic criteria, which required the adjustment of studies that reported Rome II criteria to Rome III criteria where necessary.

In the 7MM, the diagnosed prevalent cases of IBS will increase from 24,414,879 cases in 2016 to 25,163,675 cases in 2026, at an Annual Growth Rate (AGR) of 0.31% per year. In the five major European markets (5EU: France, Germany, Italy, Spain, and UK), the diagnosed prevalent cases of IBS will increase from 9,184,511 cases in 2016 to 9,371,952 cases in 2026, at an AGR of 0.20%. When examining the AGR by individual market, GlobalData forecasts that all markets except Germany and Japan will see an increase in the diagnosed prevalent cases of IBS during the forecast period.

Scope

- The Irritable bowel syndrome (IBS) EpiCast Report provides an overview of the risk factors and global trends of IBS in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- It includes a 10-year epidemiological forecast for the total and the diagnosed prevalent cases of IBS. Diagnosed prevalent cases are segmented by age (18 years and older), sex, and clinical subtypes of predominant bowel habits (diarrhea-predominant IBS [IBS-D], constipation-predominant IBS [IBS-C], and mixed-presentation IBS [IBS-M]), and comorbid conditions (anxiety and depression).
- The IBS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The IBS EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global IBS market.
- Quantify patient populations in the global IBS market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for IBS therapeutics in each of the markets covered.
- Understand magnitude of IBS population by disease type and comorbidities.
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Irritable Bowel Syndrome: Executive Summary 4
2.1 Related Reports 5
2.2 Upcoming Related Reports 6
3 Epidemiology 7
3.1 Disease Background 7
3.2 Risk Factors and Comorbidities 8
3.3 Global and Historical Trends 9
3.3.1 US 11
3.3.2 5EU 12
3.3.3 Japan 12
3.4 Forecast Methodology 13
3.4.1 Sources 13
3.4.2 Forecast Assumptions and Methods 17
3.5 Epidemiological Forecast for IBS (2016-2026) 23
3.5.1 Total Prevalent Cases of IBS 23
3.5.2 Diagnosed Prevalent Cases of IBS 24
3.5.3 Age-Specific Diagnosed Prevalent Cases of IBS 24
3.5.4 Sex-Specific Diagnosed Prevalent Cases of IBS 25
3.5.5 Diagnosed Prevalent Cases of IBS by Clinical Subtypes 26
3.5.6 Diagnosed Prevalent Cases of IBS Subtypes with Comorbidity 27
3.6 Discussion 28
3.6.1 Epidemiological Forecast Insight 28
3.6.2 Limitations of the Analysis 29
3.6.3 Strengths of the Analysis 30
4 Appendix 31
4.1 Bibliography 31
4.2 About the Authors 35
4.2.1 Epidemiologist 35
4.2.2 Reviewers 35
4.2.3 Global Director of Therapy Analysis and Epidemiology 36
4.2.4 Global Head and EVP of Healthcare Operations and Strategy 36
4.3 About GlobalData 37
4.4 Contact Us 37
4.5 Disclaimer 37

1.1 List of Tables
Table 1: Risk Factors and Comorbidities for IBS 8
Table 2: Comparison of the IBS Diagnostic Criteria Used in Epidemiological Studies 10
Table 3: 7MM, Total Prevalent Cases of IBS, Both Sexes, Ages 18 Years, N, Selected Years from 2016-2026 23
Table 4: 7MM, Diagnosed Prevalent Cases of IBS, Both Sexes, Ages 18 Years, N, Selected Years from 2016-2026 24
Table 5: 7MM, Diagnosed Prevalent Cases of IBS by Clinical Subtypes, Both Sexes, Ages 18 Years, N, 2016 27
Table 6: 7MM, Diagnosed Prevalent Cases of IBS Subtypes with Comorbidity, Both Sexes, Ages 18 Years, N, 2016 28

1.2 List of Figures
Figure 1: 7MM, Diagnosed Prevalent Cases of IBS, Both Sexes, Ages 18 Years, 2016 and 2026 5
Figure 2: 7MM, Age-Standardized Diagnosed Prevalence of IBS, Ages 18 Years, 2016 11
Figure 3: 7MM, Sources Used and Not Used, Total Prevalent Cases of IBS 13
Figure 4: 7MM, Sources Used, Diagnosed Prevalent Cases of IBS 14
Figure 5: 7MM, Sources Used , Diagnosed Prevalent Cases of IBS Clinical Subtypes 15
Figure 6: 7MM, Sources Used , Diagnosed Prevalent Cases of IBS With Comorbidity 16
Figure 7: 7MM, Age-Specific Diagnosed Prevalent Cases of IBS, Both Sexes, Ages 18 Years, N, 2016 25
Figure 8: 7MM, Sex-Specific Diagnosed Prevalent Cases of IBS, Both Sexes, Ages 18 Years, N, 2016 26

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *